SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76922.64
443.97 (0.58%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
91	Aarti Drugs Ltd.	Q V+ PT	3,449 Small Cap	375.25 (-0.70%)	17.57	2.21	5.74	4.42	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
92	Unichem Laboratories Ltd.	Q V PT	3,270 Small Cap	473.85 (2.03%)	20.99	1.28	13.92	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
93	Panacea Biotec Ltd.	Q V+ PT	3,470 Small Cap	543.85 (-4.02%)	N/A	11.68	-8.75	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
94	Kwality Pharmaceuticals Ltd.	Q V+ PT	2,908 Small Cap	2,704.70 (-3.48%)	41.67	8.44	21.70	37.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
95	Dishman Carbogen Amcis Ltd.	Q V+ PT	2,748 Small Cap	175.70 (0.26%)	28.27	0.41	5.82	-33.01	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
96	Solara Active Pharma Sciences Ltd.	Q V PT	2,784 Small Cap	567.75 (-1.61%)	N/A	2.18	-0.58	-134.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
97	Hikal Ltd.	Q V+ PT	2,728 Small Cap	218.70 (-1.15%)	N/A	2.25	4.29	-1.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
98	Fischer Medical Ventures Ltd.	Q V PT	2,735 Small Cap	40.96 (-1.96%)	N/A	8.58	96.10	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
99	Vimta Labs Ltd.	Q V+ PT	2,625 Small Cap	583.35 (-0.72%)	33.62	5.8	14.27	28.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
100	Dr Agarwals Eye Hospital Ltd.	Q V PT	2,465 Small Cap	5,027.55 (-1.42%)	34.66	7.02	17.68	31.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
101	KMC Speciality Hospitals (India) Ltd.	Q V PT	2,238 Small Cap	140.65 (2.48%)	N/A	N/A	19.21	12.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
102	Indoco Remedies Ltd.	Q V+ PT	2,206 Small Cap	236.85 (-0.90%)	N/A	1.99	6.54	-182.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
103	Shalby Ltd.	Q V PT	1,896 Small Cap	174.65 (-0.48%)	16.71	1.51	12.52	25.39	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
104	Hester Biosciences Ltd.	Q V PT	1,839 Small Cap	2,193.45 (1.48%)	35.81	4.84	6.98	0.80	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
105	Krsnaa Diagnostics Ltd.	Q V+ PT	1,764 Small Cap	551.65 (1.44%)	17.64	1.83	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
106	Windlas Biotech Ltd.	Q V PT	1,770 Small Cap	861.85 (0.47%)	26.77	3.33	18.24	17.22	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
107	Jagsonpal Pharmaceuticals Ltd.	Q V+ PT	1,558 Small Cap	237.90 (0.53%)	36.35	6.59	11.13	39.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
108	Suraksha Diagnostic Ltd.	Q V PT	1,417 Small Cap	268.15 (-1.47%)	43.39	5.7	9.86	-51.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
109	Tarsons Products Ltd.	Q V+ PT	1,426 Small Cap	261.40 (-2.46%)	61.38	2.06	12.30	-1.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
110	Syncom Formulations (India) Ltd.	Q V PT	1,340 Small Cap	14.42 (1.19%)	17.83	3.29	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
111	Lincoln Pharmaceuticals Ltd.	Q V PT	1,250 Small Cap	621.10 (-0.45%)	14.15	1.64	10.63	11.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
112	GPT Healthcare Ltd.	Q V PT	1,216 Small Cap	149.85 (1.15%)	29.12	4.56	13.96	24.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
113	Laxmi Dental Ltd.	Q V PT	1,238 Small Cap	223.05 (-1.00%)	74.63	4.96	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
114	Bajaj Healthcare Ltd.	Q V PT	1,181 Small Cap	345.25 (-1.57%)	54.54	2.18	5.76	2.91	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
115	Fermenta Biotech Ltd.	Q V PT	1,045 Small Cap	354.50 (-0.11%)	16.23	2.47	7.46	0.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
116	Gujarat Kidney And Super Speciality Ltd.	Q V+ PT	1,023 Small Cap	131.05 (1.04%)	104.36	4.19	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
117	3B Blackbio Dx Ltd.	Q V PT	1,003 Small Cap	1,197.70 (2.49%)	20.84	3.77	46.29	132.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
118	Themis Medicare Ltd.	Q V PT	1,007 Small Cap	110.60 (1.19%)	N/A	3.8	15.00	7.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
119	Health X Platform Ltd.	Q V PT	968 Small Cap	317.05 (4.22%)	N/A	3.72	109.54	-201.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
120	Wanbury Ltd.	Q V+ PT	983 Small Cap	288.20 (2.42%)	15.23	6.97	10.29	30.27	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Morepen Laboratories	62.61	5.85%
Shree Ganesh Remed.	671.85	5.76%
Blue Jet Healthcare	549	4.67%
Health X Platform	317.05	4.22%
Viyash Scientific	288.10	4.12%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Shilpa Medicare	570.85	-4.63%
Panacea Biotec	543.85	-4.02%
Kwality Pharma	2,704.70	-3.48%
Gufic Biosciences	394.25	-3.05%
Bliss GVS Pharma	524.85	-2.76%

News about Top Pharma Companies in India

Jul, 2026

Windlas Biotech submits AGM notice

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with Schedule III of the said Regulations, Windlas Biotech has informed that it enclosed a copy of the Notice of the 25th Annual General Meeting (AGM) of the Company scheduled to be held on Thursday, July 23, 2026 at 01.00 PM (IST) through Video Conferencing (VC)/Other Audio ,Visual Means (OAVM), in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. ln compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the Listing Regulations, the Company is pleased to provide to its Members, facility to exercise their right to vote at the 25th AGM scheduled to be held on July 23, 2026, by electronic means and the business mentioned in the AGM Notice may be transacted through e-voting services provided by MUFG Intime India at https://instavote.linkintime.co.in/. The Company has fixed July 16, 2026 as the ‘cut-off date’ for ascertaining the names of members, holding shares of the Company, who will be entitled to cast their votes electronically during July 20, 2026 (9:00 AM) to July 22, 2026 (5:00 PM) and also during AGM in respect of business to be transacted at the aforesaid AGM and for the purpose of receiving dividend, if any.

The above information is a part of company’s filings submitted to BSE.

Jun, 2026

Vimta Labs informs about closure of trading window

Vimta Labs has informed that as per the provisions of the Company’s code of conduct for prevention of Insider Trading, the Trading Window for transactions in shares of the Company for all designated persons, their immediate relatives and all connected persons under the code will remain closed from 1stJuly 2026 till 48 hours post declaration of unaudited financial results of the Company for the first quarter ended 30th June 2026.

The above information is a part of company’s filings submitted to BSE.

Jun, 2026

Jagsonpal Pharma inks definitive pact to acquire 85% equity stake in Aequitas

The total consideration for 85% stake would be Rs 20.8 crore, which shall be funded from internal accruals of the company

Jun, 2026

Tarsons Products informs about trading window closure

Tarsons Products has informed that in terms of the Company’s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, read with SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the securities of Tarsons Products (the Company) will remain closed for all Designated Persons and their immediate relatives with effect from Wednesday, July 01, 2026 until 48 hours after the declaration and dissemination of the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. Accordingly, all the Designated Persons have been intimated not to trade in the securities of the Company during the aforesaid period of closure of the Trading Window.

The above information is a part of company’s filings submitted to BSE.

Jun, 2026

Health X Platform informs about earnings call transcript

In furtherance to letter dated June 2, 2026 intimating that a Group Conference Call with investors and analysts was scheduled to be held on 12th June, 2026 at 4.00 PM (IST) to discuss the performance for the quarter and year ended March 31, 2026 and updates of the Company. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Health X Platform has informed that it enclosed a copy of the transcript of the said call with the Investors and analysts. The link of the transcript of the said call has been uploaded on the website of the Company. http://healthxplatform.com/Pdf/HXPL_Q4_FY26_Earnings_Group_Conference_Call_Transcript.pdf

The above information is a part of company’s filings submitted to BSE.

Jun, 2026

Hester Biosciences informs about press release

Hester Biosciences has informed that it enclosed a copy of each newspaper clipping of the advertisement published on 19 June 2026 on Notice of 39th Annual General Meeting, Dividend details and e-voting information to Members, in Ahmedabad edition of the following newspapers: Financial Express (English), and Financial Express (Gujarati).

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Sun Pharmaceutical Industries Ltd.	4,46,924 Crore
2	Divis Laboratories Ltd.	1,74,619 Crore
3	Torrent Pharmaceuticals Ltd.	1,56,450 Crore
4	Apollo Hospitals Enterprise Ltd.	1,24,925 Crore
5	Cipla Ltd.	1,18,361 Crore
6	Dr. Reddys Laboratories Ltd.	1,13,253 Crore
7	Max Healthcare Institute Ltd.	1,09,908 Crore
8	Zydus Lifesciences Ltd.	1,10,942 Crore
9	Lupin Ltd.	1,10,657 Crore
10	Mankind Pharma Ltd.	1,05,169 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,567	54,051	34.83	11.32	23.76	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,642	1,56,450	72.32	18.65	38.09	29.04
Ajanta Pharma Ltd. (M)	Very Good	3,347	42,762	40.49	9.45	27.36	25.35
Lupin Ltd. (M)	Somewhat Good	2,397	1,10,657	20.75	4.93	12.00	20.83
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,942	22.01	4.27	13.50	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,494	81,996	100
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,296	36,855	39.46
Aurobindo Pharma Ltd. (M)	Very Good	1,553	90,671	37.11
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,642	1,56,450	35.87
Ajanta Pharma Ltd. (M)	Very Good	3,347	42,762	33.57
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,296	36,855	54.67	9.13	33.11	15.51
Mankind Pharma Ltd. (M)	Very Good	2,490	1,05,169	51.62	6.41	32.39	14.65
Ajanta Pharma Ltd. (M)	Very Good	3,347	42,762	40.49	9.45	27.36	13.54
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,339	1,13,253	26.99	2.99	14.87	13.26
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,642	1,56,450	72.32	18.65	38.09	11.80

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,942	22.01	4.27	13.50	30.57
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,866	4,46,924	38.93	5.35	22.30	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,339	1,13,253	26.99	2.99	14.87	22.29
Abbott India Ltd. (M)	Very Good	25,567	54,051	34.83	11.32	23.76	18.78
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,158	62,222	45.69	5.92	12.13	14.41

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Windlas Biotech submits AGM notice

Vimta Labs informs about closure of trading window

Jagsonpal Pharma inks definitive pact to acquire 85% equity stake in Aequitas

Tarsons Products informs about trading window closure

Health X Platform informs about earnings call transcript

Hester Biosciences informs about press release

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.